ERBB2 and breast carcinoma: In this study, we address this gap by systematically evaluating CHCP-induced electroporation across four biologically distinct breast cancer cell lines: triple-negative (MDA-MB-231, Hs578T), ER+/PR+/HER2− (MCF-7), and ER+/PR+/HER2+ (BT-474).